• Profile
Close

Evaluating the efficacy and safety of topical sirolimus 0.2% cream as adjuvant therapy with pulsed dye laser for the treatment of port wine stain: A randomized, double‐blind, placebo‐controlled trial

Journal of Cosmetic Dermatology Dec 15, 2020

Fallahi M, Hallaji Z, Tavakolpour S, et al. - In this randomized double‐blind placebo‐controlled trial, researchers tested the effectiveness and safety of topical sirolimus (Rapamycin) 0.2% cream as adjuvant therapy for pulsed dye laser (PDL) for port wine stain (PWS). Fifteen patients with PWS were recruited in this analysis. Each lesion was divided into upper and lower parts, and each part was randomly allocated to receive PDL (4 sessions, 2 months apart) plus sirolimus vs PDL and placebo. The most common adverse effects in the sirolimus group were itching and dryness, contact dermatitis, and none of these were found with placebo. Although the improvement was important subjectively, as an adjuvant to PDL, topical sirolimus 0.2% does not appear to enhance PWS erythema through calorimetric evaluation.

Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay